ArticleInternational journal of nanomedicine2018
Chitosan-based nanoformulated (-)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis.
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07149506 (Efficacy of Oral or Topical Catechins vs. Placebo as an Adjuvant for the Prevention and Management of Radiation Dermatitis in Oncology Patients), which is not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Oral or Topical Catechins vs. Placebo as an Adjuvant for the Prevention and Management of Radiation Dermatitis in Oncology Patients: a Randomized Trial
Who cites it
35 citing papers in PubMed, 75 citations in OpenAlex.
- Harnessing Antioxidant Properties of Plant-Derived Bioactive Compounds to Alleviate Atopic Dermatitis Symptoms: A Review.Current pharmaceutical design · 2026Review
- Reactive oxygen species in skin diseases: pathogenic mechanisms and nanomaterial-based therapeutic strategies.Frontiers in bioengineering and biotechnology · 2026Review
- Intelligent transdermal nanoparticles as synergizing advanced delivery systems for precision therapeutics.Materials today. Bio · 2025Review
- Chitosan Nanoparticles Loaded with Polyphenols for Cosmeceutical Applications: A State-of-the-Art Review.Pharmaceutics · 2025Review
- Targeting psoriatic inflammation with natural compounds: mechanistic insights and therapeutic promise.Inflammopharmacology · 2025Review
- Antioxidant Naturally Occurring Pleiotropically Acting Bioactive Compounds, as Polymeric Nanotherapeutics Against Autoimmune Diseases Progression.Current issues in molecular biology · 2025Review
- Green Tea Catechins and Skin Health.Antioxidants (Basel, Switzerland) · 2024Review
- Oxidative Imbalance in Psoriasis with an Emphasis on Psoriatic Arthritis: Therapeutic Antioxidant Targets.Molecules (Basel, Switzerland) · 2024Review
- Nanocarrier-Based Transdermal Drug Delivery Systems for Dermatological Therapy.Pharmaceutics · 2024Review
- Unlocking the potential of flavonoid-infused drug delivery systems for diabetic wound healing with a mechanistic exploration.Inflammopharmacology · 2024Review
- Gentiopicrin-Loaded Chitosan Nanoparticles as a Topical Agent for the Treatment of Psoriasis.Nanomaterials (Basel, Switzerland) · 2024Article
- Recent Approaches for the Topical Treatment of Psoriasis Using Nanoparticles.Pharmaceutics · 2024Review
- The Commonly Used Stabilizers for Phytochemical-Based Nanoparticles: Stabilization Effects, Mechanisms, and Applications.Nutrients · 2023Review
- Review
- Efficacy of stem cell secretome loaded in hyaluronate sponge for topical treatment of psoriasis.Bioengineering & translational medicine · 2023Article
- Modulating Inflammation-Mediated Diseases via Natural Phenolic Compounds Loaded in Nanocarrier Systems.Pharmaceutics · 2023Review
- Polymeric Nanoparticles as Tunable Nanocarriers for Targeted Delivery of Drugs to Skin Tissues for Treatment of Topical Skin Diseases.Pharmaceutics · 2023Review
- Possible Mechanisms of Oxidative Stress-Induced Skin Cellular Senescence, Inflammation, and Cancer and the Therapeutic Potential of Plant Polyphenols.International journal of molecular sciences · 2023Review
- EGCG identified as an autophagy inducer for rosacea therapy.Frontiers in pharmacology · 2023Article
- The Anti-Inflammatory and Immunomodulatory Activities of Natural Products to Control Autoimmune Inflammation.International journal of molecular sciences · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundPsoriasis is a chronic and currently incurable inflammatory skin disease characterized by hyperproliferation, aberrant differentiation, and inflammation, leading to disrupted skin barrier function. The use of natural agents that can abrogate these effects could be useful for the treatment of psoriasis. Earlier studies have shown that treatment of keratinocytes and mouse skin with the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) mitigated inflammation and increased the expression of caspase-14 while promoting epidermal differentiation and cornification. However, bioavailability issues have restricted the development of EGCG for the treatment of psoriasis. MATERIALS AND
methodsTo overcome these limitations, we employed a chitosan-based polymeric nanoparticle formulation of EGCG (CHI-EGCG-NPs, hereafter termed nanoEGCG) suitable for topical delivery for treating psoriasis. We investigated and compared the efficacy of nanoEGCG versus native or free EGCG in vitro and in an in vivo imiquimod (IMQ)-induced murine psoriasis-like dermatitis model. The in vivo relevance and efficacy of nanoEGCG formulation (48 µg/mouse) were assessed in an IMQ-induced mouse psoriasis-like skin lesion model compared to free EGCG (1 mg/mouse).
resultsLike free EGCG, nanoEGCG treatment induced differentiation, and decreased proliferation and inflammatory responses in cultured keratinocytes, but with a 4-fold dose advantage. Topically applied nanoEGCG elicited a significant (
conclusionBased on these observations, our nanoEGCG formulation represents a promising drug-delivery strategy for treating psoriasis and possibly other inflammatory skin diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.